Craft

Pacific Edge

Stock Price

$0.1

2023-12-28

Market Capitalization

$94.9 M

2023-12-28

Revenue

$19.6 M

FY, 2023

Pacific Edge Summary

Company Summary

Overview
Pacific Edge is a cancer diagnostics company. It specializes in the discovery of diagnostic and prognostic non-invasive Cxbladder bladder tests for the detection and monitoring of cancer. The company covers the areas of the bladder, gastric, colorectal and endometrial cancers, and melanoma.
Type
Public
Status
Active
Founded
2001
HQ
Dunedin, NZ | view all locations
Website
https://www.pacificedgedx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Chris Gallaher, Chairman

    • Anatole Masfen, Director

      • Sarah Park, Director

        • Bryan Williams, Director

          LocationsView all

          2 locations detected

          • Dunedin, OTA HQ

            New Zealand

            87 Saint David Street, North Dunedin

          • Singapore

            Singapore

            31 Rochester Dr

          Pacific Edge Financials

          Summary Financials

          Revenue (H1, 2024)
          $13.1M
          Gross profit (H1, 2024)
          $14.0M
          Net income (H1, 2024)
          ($15.3M)
          Cash (H1, 2024)
          $20.5M
          EBIT (H1, 2024)
          ($17.8M)
          Enterprise value
          $52.5M

          News

          Footer menu